Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). | Tony et al. Arthritis Research Therapy 2011 13 R75 http content 13 3 R75 RESEARCH ARTICLE Open Access Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases experience from a national registry GRAID I 12nC-Pữtữr Too 1 R irmocfor2 I IdnHriL ilvơ-k nnnc3 K latkiiac rpn mko3 Inorn I lotìoc4 Ifì2 l fAttiCir4 Hdlb Peter ioi iy Gel Duimcbtcl HcHII cuize Koops IVIdtldb uiunxc Joerg HcHcb Ilia KUtter 11 I z l I I I I I z Z i z tz6C i l z t s I z rv r 7 R A z z z I I I 1Pk I 4- 7 7 D z PkZ r r Eir Z Az r Dz t 7 8 C zv t I hz h n Judith Haas Leonore unger Svjetlana Lovnc Marion Haubitz Rebecca Fischer-Detz Gamal Chehab Andrea Rubbert-Rotn9 Chrlstof Specker10 Jutta Welnerth11 Julia Holle12 Ulf Muller-Ladner13 Ramona Konig13 Christoph Fiehn14 Philip Durgwlnkel2 Klemens Dudde2 Helmut Sorensen15 Michael Meurer16 Martin Arlnger16 Dernd Kieseier8 Cornelia Erfurt-Derge17 Michael Sticherling17 Roland Veelken17 Ulf Ziemann18 Frank Strutz19 20 21 22 23 24 Praxis von Wussow Florian MP Meier Nico Hunzelmann Enno Schmidt Raoul Dergner Andreas Schwarting25 Rudiger Eming26 Michael Hertl26 Rudolf Stadler27 Michael Schwarz-Eywill28 Siegfried Wassenberg29 Martin Fleck30 Claudia Metzler31 Uwe Zettl32 Jens Westphal33 Stefan Heitmann34 A z z I I_I r v 7r Z t 35 I_I zt I z -7 A I zt z z l 135 A Ỉ I Z I IZ I I s lzz r 36 c It ỉ Z c r m I Z lt 36 l i I I r p rz ì rr r zt I 36 I p. z zv t r Px zA z z zt z2 mrl Anna L Herzog Heinz Wiendl Waltraud Jakob Elvira Schmidt Klaus Freivogel Ihomas Dorner and GRAID investigators Abstract Introduction Evidence from a number of open-label uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases within rheumatology nephrology dermatology and neurology other than .
